NCI COVID-19 in Cancer Patients
NCI COVID-19 in Cancer Patients, or NCCAPS Study
This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19. The Principal Investigators of this study are Dr. Beth Y. Karlan and Dr. Gottfrield Konecny.
Participants must meet the following criteria:
- Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) that fits into any one of the following categories:
- Patient is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) for metastatic cancer. Eligible treatment types are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGF-R inhibitor), endocrine therapy, or radiation therapy; or
- Patients is receiving adjuvant treatment for non-metastatic (stage I-III) cancer and has received intravenous chemotherapy, immunotherapy, targeted therapy, or radiation therapy within the past 6 weeks; or
- Patient has received an allogenic stem cell transplant or chimeric antigen receptor (CAR)-T cell or other modified cellular therapy at any time; or
- Patient is currently receiving treatment or prophylaxis for graft versus (vs.) host disease; or
- Patient has received an autologous bone marrow transplant within the past 2 years.
- Patient must have a documented positive SARS CoV-2 test. The positive test results must have been received no earlier than 14 days prior to enrollment. The test must have been ordered by a doctor's office, hospital, or department of public health. Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the SARS CoV-2 test.
Of note, patients who have recently received a SARS CoV-2 test may also be eligible to sign consent but will only be enrolled if final test result is positive.
If you would like more information please contact the Women’s Health Clinical Research Unit.
Email: email@example.com or Call: 310-794-9652.